MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

AEterna Zentaris Company Profile (NASDAQ:AEZS)

Consensus Ratings for AEterna Zentaris (NASDAQ:AEZS) (?)
Ratings Breakdown: 3 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $10.67 (254.37% upside)

Analysts' Ratings History for AEterna Zentaris (NASDAQ:AEZS)
Show:
DateFirmActionRatingPrice TargetActions
6/15/2016Maxim GroupReiterated RatingBuy$11.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/4/2016Canaccord GenuityReiterated RatingBuy$13.00 -> $9.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/2/2015HC WainwrightBoost Price TargetBuy$11.00 -> $12.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/28/2014 forward)
Earnings History for AEterna Zentaris (NASDAQ:AEZS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
3/29/2016Q415($1.30)($1.46)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/5/2015Q315($0.06)($0.07)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/13/2015Q215($0.08)($0.14)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/8/2015($0.10)($0.13)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/17/2015Q414($0.16)$0.06ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/4/2014($0.16)($0.20)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/8/2014($0.30)($0.08)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/20/2014Q413($0.04)($0.22)$12.41 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/21/2013Q412($0.31)($0.29)$7.96 million$9.16 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/13/2012Q312($0.43)($0.35)$8.38 million$7.10 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for AEterna Zentaris (NASDAQ:AEZS)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividend History for AEterna Zentaris (NASDAQ:AEZS)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for AEterna Zentaris (NASDAQ:AEZS)
No insider trades for this company have been tracked by MarketBeat.com

Latest Headlines for AEterna Zentaris (NASDAQ:AEZS)
DateHeadline
06/25/16 02:21 PMWill AEterna Zentaris Inc. (USA) Short Squeeze Soon? The Stock Just Gapped Down - Press Telegraph
06/24/16 10:17 AMAre Analysts Bearish AEterna Zentaris Inc. (USA) (NASDAQ:AEZS) After Last Week? - Engelwood Daily
06/23/16 10:04 AMStrong Buy Calls Count For AEterna Zentaris Inc. (NASDAQ:AEZS) At 3 - Investor Newswire
06/21/16 07:06 AMAEterna Zentaris Inc. (AEZS) Current Analyst Ratings - Fiscal Standard
06/20/16 02:19 PMAEterna Zentaris Inc. (AEZS) Analyst Price Targets For The Coming Week - Fiscal Standard
06/16/16 09:49 AM05.23.2016 Aeterna Zentaris Elects Ms. Carolyn Egbert as Independent Chair of the Board - [at noodls] - CHARLESTON, S.C.--(BUSINESS WIRE)--Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the 'Company'), a specialty biopharmaceutical company engaged in developing and commercializing novel treatments in oncology, ...
06/16/16 09:39 AM06.14.2016 Aeterna Zentaris Announces IND Submission by Sinopharm A-Think - [at noodls] - CHARLESTON, S.C.--(BUSINESS WIRE)--Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the 'Company') today announced that its licensee, Sinopharm A-Think Pharmaceuticals Co., Ltd. ('Sinopharm A-Think'), ...
06/16/16 09:39 AM06.06.2016 Aeterna Zentaris Reconfirms Commitment to LHRH-receptor Targeting Zoptrex™ During 2016 ASCO Annual Meeting - [at noodls] - CHARLESTON, S.C.--(BUSINESS WIRE)--Aeterna Zentaris Inc. (NASDAQ: AEZS; TSX: AEZ) (the 'Company') today reconfirmed its commitment to LHRH-receptor targeted therapy and its expectation that the pivotal, ...
06/15/16 07:24 PMTrend Of Rating Given To AEterna Zentaris Inc. (NASDAQ:AEZS) - Investor Newswire
06/15/16 02:21 PMMaxim Reiterates Buy on AEterna Zentaris Inc. (USA) (AEZS) Following IND Submission for Zoptrex in China - Smarter Analyst
06/14/16 04:00 PMAeterna Zentaris Announces IND Submission by Sinopharm A-Think - [Business Wire] - Aeterna Zentaris Inc. today announced that its licensee, Sinopharm A-Think Pharmaceuticals Co., Ltd. , which is affiliated with the largest state-owned pharmaceutical company in the People’s Republic of China, today submitted an Investigational New Drug application for Zoptrex™ to the Chinese State Food and Drug Administration , remaining on track to commence its clinical program during the first half ...
06/07/16 10:43 AMPremarket Runners: Biogen Inc. (NASDAQ:BIIB), AEterna Zentaris Inc. (USA)(NASDAQ:AEZS) - iStreetWire
06/07/16 10:43 AMSarepta Therapeutics Inc, AEterna Zentaris Inc, Zillow Group Inc, ProNAi Therapeutics Inc Among Top Pre-Market ... - TCC
06/06/16 07:57 PMCompany Update (NASDAQ:AEZS): AEterna Zentaris Inc. (USA) Reconfirms Commitment to LHRH-receptor Targeting ... - Smarter Analyst
06/06/16 04:33 PMBRIEF-Aeterna zentaris to file a NDA for zoptrex in first half of 2017 - * Aeterna Zentaris reconfirms commitment to LHRH-receptor targeting zoptrex during 2016 ASCO annual meeting
06/05/16 10:12 AMNext Weeks Broker Price Targets For AEterna Zentaris Inc. (AEZS) - Share Trading News
06/02/16 08:39 AMÆterna Zentaris, Inc. :AEZS-US: Earnings Analysis: Q1, 2016 By the Numbers : June 2, 2016 -
05/30/16 11:45 PMStock Review and Earnings Check on AEterna Zentaris Inc. (NASDAQ:AEZS) - HNN - Stock Review and Earnings Check on AEterna Zentaris Inc. (NASDAQ:AEZS)HNNCurrently, sell-side analysts are expecting AEterna Zentaris Inc. (NASDAQ:AEZS) to report quarterly EPS of $-1.19. The company's next earnings report is expected to be published on or around 2016-08-11 for the period ending on 2016-06-30. The company ...and more »
05/26/16 08:57 PMBroker Roundup For AEterna Zentaris Inc. (AEZS) - Share Trading News - Broker Roundup For AEterna Zentaris Inc. (AEZS)Share Trading NewsThe Company has three wholly owned direct and indirect subsidiaries: AEZS GmbH, based in Frankfurt, Germany, Zentaris IVF GmbH, a direct wholly owned subsidiary of AEZS Germany based in Frankfurt, Germany, and Aeterna Zentaris, Inc. Its drug ...and more »
05/24/16 03:49 PMStock Update (NASDAQ:AEZS): AEterna Zentaris Inc. (USA) Elects Ms. Carolyn Egbert as Independent Chair of the Board - Smarter Analyst - Smarter AnalystStock Update (NASDAQ:AEZS): AEterna Zentaris Inc. (USA) Elects Ms. Carolyn Egbert as Independent Chair of the BoardSmarter AnalystAEterna Zentaris Inc. (USA) (NASDAQ:AEZS), a specialty biopharmaceutical company engaged in developing and commercializing novel treatments in oncology, endocrinology and women's health, today announced the separation of the positions of ...AEterna Zentaris Names Carolyn Egbert as Independent Chair (NASDAQ:AEZS)Sonoran Weekly Reviewall 3 news articles »
05/24/16 07:19 AMEarnings Review and Stock Rundown for AEterna Zentaris Inc. (NASDAQ:AEZS) - Wall Street Hints and News - Earnings Review and Stock Rundown for AEterna Zentaris Inc. (NASDAQ:AEZS)Wall Street Hints and NewsInvestors and analysts will be paying close attention when the company posts earnings results. Earnings numbers can provide insight into a company's overall profitability. Covering equity analysts are expecting AEterna Zentaris Inc. (NASDAQ:AEZS) to ...and more »
05/23/16 07:15 PMAeterna Zentaris Elects Ms. Carolyn Egbert as Independent Chair of the Board - [Business Wire] - Aeterna Zentaris Inc. , a specialty biopharmaceutical company engaged in developing and commercializing novel treatments in oncology, endocrinology and women’s health, today announced the separation of the positions of Chairman of the Board and President and Chief Executive Officer.
05/18/16 07:49 AMAeterna Zentaris Incorporated (NASDAQ:AEZS) Shorted Shares Decreased By 24.11% - Wall Street Hints and News - Aeterna Zentaris Incorporated (NASDAQ:AEZS) Shorted Shares Decreased By 24.11%Wall Street Hints and NewsThe Firm has three wholly owned direct and indirect subsidiaries: AEZS GmbH, based in Frankfurt, Germany, Zentaris IVF GmbH, a direct wholly owned subsidiary of AEZS Germany based in Frankfurt, Germany, and Aeterna Zentaris, Inc. It currently has ...and more »
05/17/16 03:39 PMShare Recap and Earnings Focus on AEterna Zentaris Inc. (NASDAQ:AEZS) - Wall Street Hints and News - Share Recap and Earnings Focus on AEterna Zentaris Inc. (NASDAQ:AEZS)Wall Street Hints and NewsAnalysts and investors are usually very focused on company earnings numbers when they are released. Company earnings are a good way to evaluate the profitability of the company. Presently, covering analysts are anticipating AEterna Zentaris Inc.and more »
05/17/16 03:39 PMAEterna Zentaris Inc. (NASDAQ:AEZS) One-Year Price Projection At $11 - Investor Newswire - AEterna Zentaris Inc. (NASDAQ:AEZS) One-Year Price Projection At $11Investor NewswireSell-side analysts are certain on the prospect of AEterna Zentaris Inc. (NASDAQ:AEZS) stock. As of 2016-05-16, the stock ABR stands at 1.25. This type of rating states that whenever a stock has a score of 5, investors should avoid investing in such stocks.and more »
05/12/16 04:00 PMAEterna Zentaris Inc. Stock Price Declines Today - B.O.D.Y Confidential - AEterna Zentaris Inc. Stock Price Declines TodayB.O.D.Y ConfidentialThe Firm has three wholly owned direct and indirect subsidiaries: AEZS GmbH, based in Frankfurt, Germany, Zentaris IVF GmbH, a direct wholly owned subsidiary of AEZS Germany based in Frankfurt, Germany, and Aeterna Zentaris, Inc. It currently has ...
05/11/16 04:07 PMConsensus Rating Review for AEterna Zentaris Inc. (NASDAQ:AEZS) - B.O.D.Y Confidential - Consensus Rating Review for AEterna Zentaris Inc. (NASDAQ:AEZS)B.O.D.Y ConfidentialEquity research analysts currently have a consensus rating of 1.25 on shares of AEterna Zentaris Inc. (NASDAQ:AEZS). Sell-side analysts will typically rate a company's stock based on extensive research. These ratings usually translate into a Buy, Sell, ...and more »
05/10/16 09:06 PMAEterna Zentaris Inc. (NASDAQ:AEZS) One-Year Mean Price Target At $11 - Investor Newswire - AEterna Zentaris Inc. (NASDAQ:AEZS) One-Year Mean Price Target At $11Investor NewswireSell-side analysts are confident on the future outlook of AEterna Zentaris Inc. (NASDAQ:AEZS) stock. As of 2016-05-09, the stock has an ABR of 1.25 rating, where number 5 denotes a Strong Sell and 1 Strong Buy. The ABR is reached on the basis of ...and more »
05/10/16 04:00 PM3 Watch-List HC Stocks: Lpath, Inc. (LPTN), AEterna Zentaris Inc. (AEZS), Atossa Genetics Inc (ATOS) - share market updates (press release) - share market updates (press release)3 Watch-List HC Stocks: Lpath, Inc. (LPTN), AEterna Zentaris Inc. (AEZS), Atossa Genetics Inc (ATOS)share market updates (press release)Shares of Lpath, Inc. (NASDAQ:LPTN) ended Monday session in red amid volatile trading. The shares closed down -0.022 points or -9.80% at $0.203 with 492,492.00 shares getting traded. Post opening the session at $0.22, the shares hit an intraday low of ...
05/10/16 03:59 PMNLNK Fails To Impress, TBPH Gets FDA Nod, It's A Make Or Break Month For TNXP - Aeterna Zentaris Inc. (AEZS) (AEZ.TO) has a couple of catalysts to watch out for in the coming months. The company's lead product candidate Zoptrex, a targeted cytotoxic therapy for endometrial cancer, is under a pivotal phase III study, which is on track ...
05/10/16 03:59 PMAeterna Zentaris posts 1st-quarter loss of $3.7 million - MONTREAL (AP) _ Aeterna Zentaris Inc. (AEZS) on Monday reported a loss of $3.7 million in its first quarter. On a per-share basis, the Montreal-based company said it had a loss of 37 cents. The drug developer posted revenue of $242,000 in the period.
05/10/16 03:00 PMAeterna Zentaris Announces Election of Directors at 2016 Shareholders' Meeting - [Business Wire] - Aeterna Zentaris Inc. , a specialty biopharmaceutical company engaged in developing and commercializing novel treatments in oncology, endocrinology and women’s health, today announced the results of the vote on directors held at its 2016 annual meeting of shareholders held earlier today on May 10, 2016.
05/10/16 02:09 AMNewLink Genetics (NLNK) Takes Drastic Plunge; Aeterna Zentaris (AEZS) Narrows Loss - At close on Monday, the biopharmaceutical company had Market Capitalization of $476.21M and NLNK stock one-year range was from $15.15 to $56.16 per share Aeterna Zentaris Inc. (Nasdaq:AEZS) stock surged $0.06 (or $1.75%) to $3.48, with a total volume of ...
05/10/16 02:09 AMAEterna Zentaris Inc. (NASDAQ:AEZS) Comprehensive Income At $1.132 For Period Ended 2015-12-31 - Stocks Daily - Franklin IndependentAEterna Zentaris Inc. (NASDAQ:AEZS) Comprehensive Income At $1.132 For Period Ended 2015-12-31Stocks DailyFor the year ended 2015-12-31, AEterna Zentaris Inc. (NASDAQ:AEZS)comprehensive income was $1.132 millions while for the quarter ended 2015-12-31, it was $1.132 millions. AEterna Zentaris Inc. (NASDAQ:AEZS) posted $-50.143 millions on ...AEterna Zentaris Inc. (AEZS) Analyst ReviewRisers & FallersAeterna Zentaris Incorporated (NASDAQ:AEZS) Short Interest Decreased By 11.62%Franklin IndependentAeterna Zentaris posts 1st-quarter loss of $3.7 millionThe Provinceall 10 news articles »
05/09/16 09:01 PMCompany Update (NASDAQ:AEZS): AEterna Zentaris Inc. (USA) Reports First Quarter 2016 Financial and Operating ... - Smarter Analyst - Smarter AnalystCompany Update (NASDAQ:AEZS): AEterna Zentaris Inc. (USA) Reports First Quarter 2016 Financial and Operating ...Smarter AnalystAEterna Zentaris Inc. (USA) (NASDAQ:AEZS), a specialty biopharmaceutical company engaged in developing and commercializing novel treatments in oncology, endocrinology and women's health, today reported financial and operating results for the first ...and more »
05/09/16 05:26 PMAeterna Zentaris reports 1Q loss -
05/09/16 04:00 PMAeterna Zentaris Reports First Quarter 2016 Financial and Operating Results - [Business Wire] - Aeterna Zentaris Inc. , a specialty biopharmaceutical company engaged in developing and commercializing novel treatments in oncology, endocrinology and women’s health, today reported financial and operating results for the first quarter ended March 31, 2016.
05/04/16 03:53 PMAverage Analyst Rating for AEterna Zentaris Inc. (NASDAQ:AEZS) - B.O.D.Y Confidential - Average Analyst Rating for AEterna Zentaris Inc. (NASDAQ:AEZS)B.O.D.Y ConfidentialWall Street analysts have provided an average broker recommendation of 1.25 on AEterna Zentaris Inc. (NASDAQ:AEZS) shares. The rating is determined by using the average of all analyst recommendations taken into consideration by Zacks Research.and more »
05/02/16 04:15 PMAEterna Zentaris Inc. (NASDAQ:AEZS) Comprehensive Income At $1.132 Millions For Quarter Closed 2015-12-31 - Stocks Daily - Web Breaking NewsAEterna Zentaris Inc. (NASDAQ:AEZS) Comprehensive Income At $1.132 Millions For Quarter Closed 2015-12-31Stocks DailyFor the year ended 2015-12-31, AEterna Zentaris Inc. (NASDAQ:AEZS) comprehensive income was $1.132 millions whereas for the quarter ended 2015-12-31, the comprehensive income was $1.132 millions. AEterna Zentaris Inc. (NASDAQ:AEZS) posted ...Maxim Group Reaffirms Buy Rating for AEterna Zentaris Inc. (AEZS)Web Breaking Newsall 2 news articles »
04/27/16 07:31 PMBRIEF-Aeterna Zentaris acquires U.S. Promotional rights for prostate cancer blood test - * Aeterna zentaris acquires exclusive u.s. Promotional rights for apifiny prostate cancer blood test Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)
04/27/16 04:09 PMAeterna Zentaris (AEZS) Announces Acquisition of Exclusive, U.S. Rights to APIFINY - StreetInsider.com - Aeterna Zentaris (AEZS) Announces Acquisition of Exclusive, U.S. Rights to APIFINYStreetInsider.comAeterna Zentaris Inc. (NASDAQ: AEZS) announced that, effective as of June 1, 2016, it has acquired the exclusive right to promote APIFINY®, the only cancer specific, non-PSA blood test to assess the risk for the presence of prostate cancer, throughout ...and more »
04/27/16 03:10 PM4:10 pm Aeterna Zentaris acquires exclusive US promotional rights for Apifiny prostate cancer blood test pursuant to a new co-marketing agreement with Armune BioScience -
04/27/16 03:05 PMAeterna Zentaris Acquires Exclusive U.S. Promotional Rights for APIFINY® Prostate Cancer Blood Test - [Business Wire] - Aeterna Zentaris Inc. today announced that, effective as of June 1, 2016, it has acquired the exclusive right to promote APIFINY®, the only cancer specific, non-PSA blood test to assess the risk for the presence of prostate cancer, throughout the entire United States pursuant to a new co-marketing agreement with Armune BioScience, Inc.
04/27/16 02:56 AMAEterna Zentaris Inc. (NASDAQ:AEZS) Share Rating Recap - B.O.D.Y Confidential - AEterna Zentaris Inc. (NASDAQ:AEZS) Share Rating RecapB.O.D.Y ConfidentialShares of AEterna Zentaris Inc. (NASDAQ:AEZS) are tracked by analysts as well as crowd investors. Research from Beta Systems keeps track of crowd sourced sentiment and provides consensus stock ratings. The rating information comes mainly from ...
04/08/16 02:00 PMAeterna Zentaris Mails Information Circular in Connection with Annual Meeting of Shareholders - [Business Wire] - Aeterna Zentaris Inc. today announced that it has mailed a Notice of Meeting and Management Information Circular to the shareholders of record as of April 1, 2016 in connection with its Annual Meeting of shareholders to be held at the offices of Norton Rose Fulbright US LLP, 666 Fifth Avenue, New York, New York 10103-3198 on Tuesday, May 10, 2016 at 10:30 a.m.
04/02/16 12:04 PMAETERNA ZENTARIS INC. Financials -
04/01/16 04:05 PMAeterna Zentaris Announces At the Market Issuance Program - [Business Wire] - Aeterna Zentaris Inc. announced today that it has entered into an At Market Issuance Sales Agreement, dated April 1, 2016, with H.C.
04/01/16 10:13 AMÆterna Zentaris, Inc. :AEZS-US: Earnings Analysis: Q4, 2015 By the Numbers -
03/29/16 04:35 PMAeterna Zentaris reports 4Q loss -
03/29/16 04:00 PMAeterna Zentaris Reports Fourth Quarter and Full-Year 2015 Financial and Operating Results - [Business Wire] - Aeterna Zentaris Inc. , a specialty biopharmaceutical company engaged in developing and commercializing novel treatments in oncology, endocrinology and women's health, today reported financial and operating results for the fourth quarter and year ended December 31, 2015.
About AEterna Zentaris

AEterna Zentaris logoAeterna Zentaris Inc. is a Canada-based specialty biopharmaceutical company engaged in developing treatments in oncology, endocrinology and women's health. The Company has three wholly owned direct and indirect subsidiaries: AEZS GmbH, based in Frankfurt, Germany, Zentaris IVF GmbH, a direct wholly owned subsidiary of AEZS Germany based in Frankfurt, Germany, and Aeterna Zentaris, Inc. Its drug development efforts are focused on two compounds, zoptarelin doxorubicin and Macrilen, which are in clinical development, and on two oncology compounds (an Erk inhibitor and Luteinizing Hormone-Releasing Hormone-disorazol Z product candidates), which are in pre-clinical development. Zoptarelin doxorubicin represents a hybrid molecule composed of a synthetic peptide carrier and a chemotherapy agent, doxorubicin. Macrilen (macimorelin acetate) is an orally available peptidomimetic ghrelin receptor agonist that stimulates the secretion of growth hormone by binding to the ghrelin receptor.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: AEZS
  • CUSIP:
Key Metrics:
  • Previous Close: $3.22
  • 50 Day Moving Average: $3.46
  • 200 Day Moving Average: $3.59
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $29.92M
  • Current Quarter EPS Consensus Estimate: $-2.84 EPS
Additional Links:
AEterna Zentaris (NASDAQ:AEZS) Chart for Tuesday, June, 28, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha